Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$28.49+0.62 (+2.22%)
Close on Nov 17, 2026Market cap $4.55BP/E –Yield –
Adaptive Biotechnologies r&d expenses
Research and development expenses are spending on new products and technology.
Adaptive Biotechnologies's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.21M, down 7.8% year over year. For fiscal 2025 it was $93.77M, down 8.9% from the year before. The highest annual figure on record is $142.34M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.77M | -8.9% |
| FY2024 | Dec 31, 2024 | $102.95M | -15.7% |
| FY2023 | Dec 31, 2023 | $122.12M | -13.9% |
| FY2022 | Dec 31, 2022 | $141.76M | -0.4% |
| FY2021 | Dec 31, 2021 | $142.34M | +22.6% |
| FY2020 | Dec 31, 2020 | $116.07M | +64.2% |
| FY2019 | Dec 31, 2019 | $70.71M | +80.6% |
| FY2018 | Dec 31, 2018 | $39.16M | +22.4% |
| FY2017 | Dec 31, 2017 | $32.00M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $19.15M | -20.6% |
| Q1 FY2026 | Mar 31, 2026 | $23.62M | -2.4% |
| Q4 FY2025 | Dec 31, 2025 | $21.76M | -6.2% |
| Q3 FY2025 | Sep 30, 2025 | $23.67M | -2.0% |
| Q2 FY2025 | Jun 30, 2025 | $24.13M | -4.8% |
| Q1 FY2025 | Mar 31, 2025 | $24.20M | -20.0% |
| Q4 FY2024 | Dec 31, 2024 | $23.19M | -19.3% |
| Q3 FY2024 | Sep 30, 2024 | $24.16M | -15.3% |
| Q2 FY2024 | Jun 30, 2024 | $25.35M | -21.4% |
| Q1 FY2024 | Mar 31, 2024 | $30.25M | -7.2% |
| Q4 FY2023 | Dec 31, 2023 | $28.75M | -7.9% |
| Q3 FY2023 | Sep 30, 2023 | $28.53M | -20.0% |
| Q2 FY2023 | Jun 30, 2023 | $32.24M | -13.0% |
| Q1 FY2023 | Mar 31, 2023 | $32.60M | -13.8% |
| Q4 FY2022 | Dec 31, 2022 | $31.22M | -10.0% |
| Q3 FY2022 | Sep 30, 2022 | $35.66M | -1.1% |
| Q2 FY2022 | Jun 30, 2022 | $37.04M | -2.0% |
| Q1 FY2022 | Mar 31, 2022 | $37.84M | +12.0% |
| Q4 FY2021 | Dec 31, 2021 | $34.70M | -3.2% |
| Q3 FY2021 | Sep 30, 2021 | $36.07M | +19.0% |
| Q2 FY2021 | Jun 30, 2021 | $37.80M | +45.4% |
| Q1 FY2021 | Mar 31, 2021 | $33.77M | +41.1% |
| Q4 FY2020 | Dec 31, 2020 | $35.83M | +69.1% |
| Q3 FY2020 | Sep 30, 2020 | $30.31M | +47.8% |
| Q2 FY2020 | Jun 30, 2020 | $25.99M | +57.3% |
| Q1 FY2020 | Mar 31, 2020 | $23.94M | +91.7% |
| Q4 FY2019 | Dec 31, 2019 | $21.19M | +91.5% |
| Q3 FY2019 | Sep 30, 2019 | $20.51M | +109.6% |
| Q2 FY2019 | Jun 30, 2019 | $16.53M | +74.9% |
| Q1 FY2019 | Mar 31, 2019 | $12.48M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.07M | – |
| Q3 FY2018 | Sep 30, 2018 | $9.78M | – |
| Q2 FY2018 | Jun 30, 2018 | $9.45M | – |
See a number that looks wrong?